<DOC>
	<DOCNO>NCT01084902</DOCNO>
	<brief_summary>Prostaglandin analog ( PGAs ) represent new class active ocular hypotensive agent possess unique mechanism action . Many study suggest 0.005 % Latanoprost effective safe anti-glaucoma medication , beta-blockers . It also find effective class anti-glaucoma medication carbonic anhydrase inhibitor alpha agonist . However data comparison lack Chinese patient . So necessary increase China experience get clinical data China . Besides latanoprost , brinzolamide know one ocular hypotensive agent less systemic adverse effect , therefore select control medication study . The administration phase 4 week long enough compare efficacy safety study drug account following-up condition China , easy investigator get enough subject limited stage observation time shorter . Before treatment study drug , previous glaucoma drug wash . The minimum washout period 5 day cholinergic agonist , 1 week adrenergic agonist , 3 week adrenergic β receptor blocker 4 week PGAS . After washout , patient randomise send two parallel study group : one group receive latanoprost 0.005 % daily evening , group receive 1.0 % Brinzolamide twice daily . Randomization obtain use list random number .During study four visit : screening , baseline , 2 week , 4 week treatment . The IOP measure Goldmann tonometer 8 visit . The tonometry perform administration dose day patient treat Brinzolamide . Three separate measurement take eye mean three measurement use statistical analysis . Best correct visual acuity refraction determine slit lamp examination , ophthalmoscopy perform visit .</brief_summary>
	<brief_title>Efficacy Comparison Xalatan Azopt POAG OH</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Brinzolamide</mesh_term>
	<criteria>1 . Diagnosed POAG OHT 2 . Older 18 year , either sex 3 . With IOP≤30mmHg eye IOP &gt; 21mmHg either eye washout 4 . Understand study instruction willing attend followup appointment 5 . Be willing comply study medication use 6 . Ready write informed consent 1 . Visual field defect within central 10° 2 . Absence vision one eye 3 . History hypersensitivity component study medication 4 . Contraindications carbonic anhydrase inhibitor prostaglandins 5 . History ocular herpetic disease , uveitis , cystoid macular edema 6 . Ocular history trauma , inflammation , surgery use corticosteroid ( within 2 month ) 7 . History ocular laser therapy within 3 month 8 . Severe dry eye 9 . Signs ocular infection , except blepharitis 10 . Corneal abnormality may affect IOP measurement 11 . Unwilling accept risk hyperchromia iris development hypertrichosis 12 . Pregnant female lactate mother</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>POAG</keyword>
	<keyword>OH</keyword>
	<keyword>Xalatan</keyword>
	<keyword>Azopt</keyword>
	<keyword>Primary Open Angle Study</keyword>
</DOC>